Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating)'s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $5.28 and traded as high as $5.88. Capricor Therapeutics shares last traded at $5.79, with a volume of 100,350 shares trading hands.
Capricor Therapeutics Trading Up 0.5 %
The stock has a 50 day moving average of $5.28 and a 200-day moving average of $4.31. The company has a market capitalization of $140.96 million, a P/E ratio of -5.57 and a beta of 4.84.
Get Capricor Therapeutics alerts:Capricor Therapeutics (NASDAQ:CAPR – Get Rating) last announced its quarterly earnings data on Wednesday, August 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). During the same quarter in the prior year, the company posted ($0.21) earnings per share. As a group, sell-side analysts expect that Capricor Therapeutics Inc will post -1.17 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in CAPR. Selective Wealth Management Inc. purchased a new position in Capricor Therapeutics in the 1st quarter worth approximately $732,000. Vanguard Group Inc. lifted its holdings in Capricor Therapeutics by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company's stock worth $3,502,000 after purchasing an additional 54,260 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Capricor Therapeutics by 54.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company's stock worth $510,000 after purchasing an additional 52,611 shares in the last quarter. Bailard Inc. purchased a new position in Capricor Therapeutics in the 2nd quarter worth approximately $104,000. Finally, UBS Group AG lifted its holdings in Capricor Therapeutics by 326.0% in the 2nd quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock worth $102,000 after purchasing an additional 22,462 shares in the last quarter. 10.43% of the stock is owned by hedge funds and other institutional investors.Capricor Therapeutics Company Profile
(Get Rating)
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
- Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.